Community Research documents how peptide practices develop outside formal trials. Reported schedules are presented as observations, not recommendations, and are kept separate from clinically studied regimens.
If MOTS-c shows how a convention forms around a single molecule, CJC-1295 and ipamorelin show how one forms around a combination. We’ve explained the underlying growth-hormone-secretagogue biology in its own article; here the interest is the pairing itself — one of the most familiar stacks in the peptide community — and the surprisingly specific, internally coherent logic the community built to justify it, resting on a thin base of human evidence.
What they are
The two peptides are paired because they push growth-hormone release through two different doors. CJC-1295 is a GHRH analog — it mimics growth-hormone-releasing hormone, the body’s own “release GH” signal. Ipamorelin is a selective growth-hormone secretagogue that acts on the ghrelin receptor, a separate pathway that also triggers GH release while, in its original characterization, sparing other hormones like cortisol. Because the two compounds act through different receptors, combined signaling can produce greater GH release in experimental settings than either pathway alone; the magnitude and pattern depend on the molecules, amounts, and study conditions. That two-pathway logic is the theoretical basis for the entire convention.
One distinction runs through all community discussion: CJC-1295 “with DAC” versus “without DAC.” The DAC (drug affinity complex) version has a long half-life and produces a sustained elevation in GH and IGF-1 over days. The no-DAC version — often labeled Mod GRF 1-29 — is short-acting and pulsatile. As we’ve flagged before, the naming here is genuinely muddled in community usage, and the two behave very differently.
What formal research has actually studied
The honest summary: there is real pharmacology here, but almost no controlled efficacy data for the way the community uses these compounds, and neither peptide is FDA approved.
For CJC-1295, an early study demonstrated that the DAC analog produced prolonged, dose-dependent increases in GH and IGF-1 in healthy adults — establishing that the molecule does what it claims to the hormone axis. For ipamorelin, the foundational 1998 work characterized it as the first selective GH secretagogue, notable for releasing GH without a strong effect on other pituitary hormones. These are legitimate pharmacology findings. What they are not is evidence that the popular nightly pairing improves body composition, recovery, or performance in the ways community goals imply — no large controlled trial has tested that combination for those outcomes.
What the community reports
The community’s practice around these two is unusually detailed and consistent, which is part of why it reads so much like an established protocol. The figures below are drawn from commonly circulated community and vendor “research” guides available as of July 2026. They are community-reported conventions, not validated regimens or recommendations.
Across the community and vendor guides reviewed for this article, the pairing is most often built on the short-acting Mod GRF 1-29 form of CJC-1295 (the no-DAC version) combined with ipamorelin, at roughly 100–300 mcg of each per injection — frequently around 100–200 mcg of each — given subcutaneously, most often once daily before bed on an empty stomach, with some using a second daily dose. The long-acting CJC-1295 with DAC is discussed as an alternative used less frequently, because its multi-day half-life produces sustained rather than pulsatile exposure. A widely repeated idea is the “saturation dose,” often described as roughly 100 mcg or approximately 1 mcg/kg for a secretagogue component, beyond which additional amounts are said to produce diminishing returns; the terminology is applied inconsistently across guides, and no controlled trial defines a universal saturation dose for the CJC-1295/ipamorelin pairing (and 100 mcg equals 1 mcg/kg only for a 100 kg person — the two figures are not automatically equivalent). Cycles are commonly described as eight to twelve weeks with a break, sometimes on a five-days-on, two-days-off pattern. Community patterns were reviewed across publicly accessible discussion and vendor materials available in July 2026; repetition is documented here as a convention, not treated as evidence of effectiveness.
| Reported convention | Apparent origin | Evidentiary status |
|---|---|---|
| Short-acting Mod GRF 1-29 paired with ipamorelin, ~100–300 mcg each | Community pulse-based convention | No controlled efficacy trial of the pairing for these goals |
| CJC-1295 with DAC used less frequently, because of prolonged exposure | Extrapolated from human pharmacokinetic data | Community schedules are not clinically validated |
| Once daily before bed, fasted | Rationale: aligning with the nocturnal GH surge | Plausible mechanistically; not established by comparative human trials |
| ”Saturation dose” ~100 mcg / ~1 mcg/kg for a secretagogue component | Extrapolated from receptor dose-response reasoning | Terminology applied inconsistently; no trial defines a universal saturation dose |
| 8–12 week cycles, sometimes 5-on/2-off | Community convention | No validated human cycle length |
Where those conventions came from
This is a case where community logic is genuinely well-reasoned — and still not the same as evidence. The two-receptor pairing, the saturation-dose idea, and the before-bed timing all follow sensibly from real endocrinology: GH is released in pulses, largely at night; GHRH and ghrelin-receptor pathways are distinct; and receptor systems do show saturable dose-response. That coherence is exactly why the convention spread so widely and feels authoritative.
But the specific numbers and schedules propagated the way they usually do — through community and vendor guides citing one another until a particular 100–200 mcg, once-nightly pattern became “the protocol.” The mechanism supports the shape of the practice; it does not validate the specific doses, and no controlled human trial has confirmed that this pairing delivers the body-composition or recovery outcomes people are after. Sound reasoning and demonstrated efficacy are different things.
What remains unknown
The gaps are real. There is no controlled human evidence that the nightly pairing improves body composition, recovery, sleep, or performance for typical users. Optimal dose, the true value of the saturation ceiling in practice, ideal cycle length, and long-term effects of sustained GH-axis stimulation are not established. The safety of chronic use is not well characterized — and elevating the GH/IGF-1 axis is not automatically benign.
As with any injectable, the numbers also assume the vial contains what the label says. A vial labeled 5 mg that actually tests at 4.3 mg makes every label-based concentration estimate about 14% high, because purity and net content answer different questions on a certificate of analysis.
Regulatory and sports context
Neither compound is FDA approved. Both appear on FDA’s list of bulk substances flagged for potential significant safety risks in compounding: for CJC-1295, FDA cites risk of immunogenicity and impurity/characterization complexities and notes it has “identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction,” with limited available clinical data. For ipamorelin, FDA cites immunogenicity and characterization concerns and a literature report of serious adverse events, including death, when ipamorelin was administered intravenously to improve gastric motility.
Both are also prohibited at all times by WADA under category S2 — CJC-1295 as a GHRH analog, ipamorelin as a growth-hormone secretagogue — alongside related compounds like sermorelin, tesamorelin, and MK-677. A tested athlete using either without an applicable Therapeutic Use Exemption risks an anti-doping rule violation.
Why it matters
CJC-1295 and ipamorelin are the series’ best example of a convention that is well-reasoned yet unproven — a distinction easy to blur precisely because the reasoning is good. The two-receptor logic is real endocrinology; the nightly, saturation-dose ritual is a coherent story; and none of it substitutes for a controlled trial showing the combination does what users want. Holding both facts at once — that the mechanism is legitimate and the specific practice is untested — is exactly the kind of clear-eyed reading this series is built to encourage.